Ignite Creation Date:
2025-12-24 @ 1:29 PM
Ignite Modification Date:
2026-01-04 @ 4:39 PM
Study NCT ID:
NCT02591095
Status:
COMPLETED
Last Update Posted:
2019-03-19
First Post:
2015-10-14
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer
Sponsor:
Centre Francois Baclesse
Organization:
Study Overview
Official Title:
A Study of ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer
Status:
COMPLETED
Status Verified Date:
2019-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MONAVI-1
Brief Summary:
ABT-263 as single agent in women with platinum resistant/refractory recurrent ovarian cancer.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: